The Pisces Party Weekend
July 29th, 2010Do or Die 02-22-10
July 28th, 2010
Past Front Page Images
July 28th, 2010
Rep. Barney Frank Totally Pawns Wingnut at Town Hall
August 19th, 2009time to go back to school.. are you?
August 17th, 2009Bidwell
Gene
Major:
Manscaping
Minor:
Surviving the Apocalypse
Backers of legal pot eye ballot
June 11th, 2009So the sfgate.com had a great article this am.. here is a snippet of it..

POT
With polls showing the legalization of marijuana gaining public support, and a state budget crisis fueling an ever-more-desperate search for revenue, backers of the first major statewide initiative to legalize marijuana for personal use – and allow counties to tax and regulate the drug – say they’re preparing to get the matter on the November 2010 ballot.
The move comes as other legislative efforts to legalize marijuana are beginning to gain traction, including a special July election in Oakland to create a category for cannabis taxes, and hearings this fall on a bill by state Assemblyman Tom Ammiano to decriminalize the substance.
With California counties and cities facing huge cuts in critical programs because of the state’s $24.3 billion budget deficit – supporters of efforts to legalize and tax marijuana have seized on a new and potentially potent financial argument to take a new look at the issue. Read More
okay so with that article there was a link to TaxCannabis2010.org an interesting site. check it out.. on the site they actually had the updated proposed language.. and well I wanted to share this with everyone.
this is still a draft. if you like to go TaxCannabis2010.org and post your comments in the fourm.
The Control, Regulate and Tax Cannabis Act of 2010
Section 1: Name
This Act shall be known as the “Control, Regulate and Tax Cannabis Act of 2010.”
Section 2: Findings and Purposes
This Act, adopted by the People of the State of California, makes the following Findings and Statement of Purpose:
1. California’s laws criminalizing marijuana (cannabis) have failed and need to be reformed. California spends spending millions in taxpayer dollars filling prisons with non-violent cannabis users, while paroling dangerous, violent criminals, putting our communities at risk.
2. When reforming our cannabis laws, we must protect:
a. The safety and privacy of our citizens.
b. The existing rights of medical patients to medical marijuana.
c. The right of local communities to control their own cannabis policies.
3. Therefore the People desire to enact a law with two sensible purposes to reform our cannabis laws:
a. Regulate cannabis like we do alcohol, allowing adults 21 years of age and older to consume and posses small amounts of cannabis in the privacy of their own homes, or within the confines of a licensed business.
b. Grant local control in California, giving local governments the power and option to tax and regulate the sale of cannabis.
4. At the same time the People wish to ensure:
a. That in any city or county that decides not to tax and regulate the sale of cannabis, that growing, buying and selling cannabis there will remain illegal, though the right of individuals to consume small amounts in the privacy of their own home will remain protected.
b. Any city or county that decides to tax and regulate the growing, buying and selling of cannabis must create a strictly controlled legal system that is limited to adults 21 and over, and will strictly regulate cultivation, distribution and sales, and that the city or county will have complete control over how and how much cannabis can be bought and sold.
5. Taxing and regulating cannabis will generate billions of dollars in annual revenues for California to fund what Californians feel matters most: jobs, health care, schools and libraries, roads, and more.
6. Decriminalizing personal, private, adult consumptionwill free up police resources, enabling law enforcement to focus on drug dealers who target our children with cannabis and other substances, and violent criminals.
7. California will save billions of dollars that would have been spent on targeting, arresting, trying, convicting, and imprisoning non-violent cannabis users. The money saved can go towards apprehending truly dangerous criminals and keeping them locked up, and towards other essential state needs.
8. Where cannabis is sold by licensed, safe, and legal businesses, street dealers will be put out of business, and their influence and affects in our communities will fade.
Section 3: Legal Possession or Consumption
Article 5 of Chapter 5 of Division 10 of the Health and Safety Code, commencing with section 11300 is added to read:
Section 11300: Lawful Possession and Private Consumption and Cultivation of Marijuana
(a) Notwithstanding any other provision of law, it is not unlawful, and shall not be a crime, misdemeanor or infraction for any person 21 years of age or older to:
(i) Privately possess, transport or consume up to one ounce of marijuana, or such other amount a local government permits pursuant to section 11301(n), solely for that individual’s private consumption, and not for sale or resale.
(ii) Cultivate on private property marijuana plants for private consumption only, by the owner or other lawful residents or visitors of the property where grown, in a space of not more than twenty-five square feet (as for example, a square plot five feet on a side) per private residence or, in the absence of a residence, the property. Provided, however, that cultivation on leased or rented property shall be subject to permission from the owner of the property.
(iii) Possess on the premises where grown the living and harvested plants and results of any harvest and processing of plants lawfully cultivated pursuant to section 11300(a)(ii), for private consumption on the premises where grown.
(iv) Possess objects, items, tools, equipment, products and materials associated with activities permitted under this subsection.
(b) “Private consumption” shall include but is not limited to possession and consumption, in any form, of marijuana in a private dwelling, whether permanent or temporary, on private property, and shall include premises open to the public that have been lawfully licensed or permitted for the private sale and on-premises consumption marijuana by a local government pursuant to section 11301.
(c) “Private consumption” shall not include, and nothing in this Act shall permit marijuana:
(i) possession for sale or resale, regardless of amount, except by a person who is licensed or permitted to do so under the terms of an ordinance adopted pursuant to section 11301;
(ii) consumption in public or in a public place;
(iii) consumption any place where children may be present, other than in a private dwelling or on private property with the permission of the owner or lessor of the property;
(iv) consumption on a school bus or in any vehicle, boat or aircraft that is being operated, or that adversely affects the operator of any vehicle, boat or aircraft.
Section 11301: Local Laws to Control, Regulate and Tax Commercial Marijuana
Notwithstanding any other provision of state or local law, a local government may adopt ordinances, regulations, or other acts having the force of law to control, license, regulate, permit or otherwise authorize, with conditions, the following:
(a) cultivation, processing, the safe and secure transportation, sale and possession for sale of marijuana, but only by persons lawfully licensed, permitted or authorized to do so;
(b) retail sale of up to one ounce per person per transaction, or such other amount as established under subsection (n), in a licensed and permitted premises, to persons 21 years or older, for personal consumption and not for resale;
(c) consumption of marijuana within licensed or permitted premises;
(d) safe and secure transportation, within the jurisdiction, of marijuana from a facility licensed or permitted for cultivation or processing, to a premises licensed or permitted for sale or sale and on-premises consumption of marijuana;
(e) prohibit and punish through civil fines or other remedies the possession, sale, or possession for sale, of marijuana that was not obtained from a licensed or permitted place of sale, cultivation, processing and transportation;
(f) appropriate limits on licensed or permitted premises for sale, or sale and on-premises use, of marijuana, including limits on zoning, locations, size, hours of operation, occupancy, protection of adjoining and nearby properties and persons from unwanted exposure, advertising, signs and displays, and other controls necessary for protection of the public health and welfare;
(g) appropriate controls on cultivation, transportation, sales, and consumption of marijuana to strictly prohibit access to minors under the age of 21;
(h) age limits to ensure that all persons present in, employed by, or in any way involved in the operation of, any such permitted or licensed business, facility or premises are 21 years of age or older;
(i) appropriate environmental and public health controls to ensure that any such permitted or licensed business, facility or premisses minimizes any harm to the environment, adjoining and nearby landowners, and persons passing by;
(j) appropriate controls to prohibit public display, use or consumption of marijuana;
(k) appropriate controls, including civil fines and penalties, to prohibit and punish cultivation, processing, transportation, sale or use of marijuana that is not authorized by law;
(l) appropriate zoning and land use controls to control the location, size or other characteristics of any permitted or licensed facility to protect the public health and welfare;
(m) appropriate taxes or fees pursuant to section 11302;
(n) such larger amounts for private possession, cultivation and possession of cultivation results within the jurisdiction than those established under section 11300(a) as the local authority deems appropriate and proper due to local circumstances;
(o) any other appropriate controls necessary for protection of the public health and welfare.
Section 11302: Imposition and Collection of Taxes and Fees
(a) Any ordinance, regulation or other act adopted pursuant to section 11301 may include imposition of appropriate general, special or excise, transfer or transaction taxes, or fees, on any activity permitted or licensed pursuant to such enactment, in order to permit the local government to raise revenue, or to recoup any direct or indirect costs associated with the permitted or licensed activity, or the permitting or licensing scheme, including without limitation: administration; applications and issuance or licenses or permits; inspection of licensed or permitted premises; enforcement; law enforcement or public safety; law enforcement against unlicensed or unpermitted activities.
(b) Any permitted or licensed business, facility, or premises shall be responsible for paying all federal, state and local taxes, fees, fines, penalties or other financial responsibility imposed on all or similarly situated businesses, facilities or premises, including without limitation income taxes business taxes, license fees and property taxes, without regard to or identification of the business or items or services sold. Provided however, that licensed or permitted sales of marijuana seeds or whole plants shall be exempt from sales taxes to the same extent that other seeds or plants are exempt.
Section 11303: Seizure
(a) Notwithstanding sections 11470 and 11479 of the Health and Safety Code, no state or local law enforcement agency or official shall attempt, threaten or in fact seize or destroy any marijuana plant, seeds or marijuana that is lawfully cultivated, processed, transported, possessed, possessed for sale, sold or used in compliance with this Act or any local government ordinance, law or regulation adopted pursuant to this Act.
Section 11304: Effect of Act and Definitions
(a) This Act is expressly intended to limit the application and enforcement of all state and local laws relating to possession, transportation, cultivation, use and sale of marijuana, including but not limited to the following, whether now existing or adopted in the future: Health and Safety Code sections 11014.5 and 11364.5 [relating to drug paraphernalia]; 11054 [relating to marijuana or tetrahydrocannabinols]; 11357 [relating to possession]; 11358 [relating to cultivation]; 11359 [possession for sale]; 11360 [relating to transportation and sales]; 11361 [relating to minors]; 11370 [relating to punishment]; 11470 [relating to forfeiture]; 11479 [relating to seizure and destruction]; 11703 [relating to definitions regarding illegal substances]; 11705 [actions for use of illegal controlled substance]; Vehicle Code sections 23222 and 40000.15 [relating to possession].
(b) This Act is not intended to affect the application or enforcement of state laws relating to public health and safety or protection of children and others, including but not limited to: Health and Safety Code sections 11357 [relating to possession on school grounds]; 11532 [relating to loitering to commit a crime or acts not authorized by law]; Vehicle Code section 23152 [relating to driving while under the influence]; Penal Code section 272 [relating to contributing to the delinquency of a minor]; nor any law prohibiting use of controlled substances in the workplace or by specific persons whose jobs involve public safety.
(c) This Act shall not be construed to affect, limit or amend any statute that forbids impairment while engaging in dangerous activities like driving, or that penalizes bringing marijuana to a school enrolling pupils in any grade from kindergarten through 12, inclusive.
(d) Definitions
For purposes of this Act:
(i) “Marijuana” means all parts of the plant Cannabis sativa L., whether growing or not; the seeds thereof; the resin extracted from any part of the plant; concentrated cannabis; edible products containing same; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds or resin.
(ii) “One ounce” means 28.35 grams.
(iii) For purposes of section 11300(a)(ii) “marijuana plant” means all parts of a living Cannabis Sativa L. plant.
(iv) In determining whether an amount of marijuana is or is not in excess of the amounts in section 11300(a), or any local ordinance or regulation adopted pursuant to 11301(l), only the amount of the marijuana in an edible marijuana product shall be included.
(v) In determining whether an amount of marijuana is or is not in excess of the amounts set forth in section 11300(a), or any local ordinance or regulation adopted pursuant to section 11301(n), living and harvested marijuana plants shall be assessed by square footage, not by weight.
(vi) In determining whether an amount of marijuana is or is not in excess of the amounts set forth in section 11300(a), or any local ordinance or regulation adopted pursuant to section 11301(n), where the marijuana is grown and harvested pursuant to section 11300(a)(iii), only the weight of the dried marijuana flowers and leaves shall be included, and such total amount on the premises may not exceed 32 ounces from one or more harvest, unless a local ordinance or regulation adopted pursuant to section 11301(l) permits a larger amount.
Section 4: Amendment
Pursuant to Article 2, section 10(c) of the California Constitution, this Act may be amended either by a subsequent measure submitted to a vote of the People at a statewide General election; or by statute validly passed by the Legislature and signed by the Governor, but only to further the purposes of the Act. Furthermore, the limitations herein on consumption, cultivation and possession and other acts are minimum thresholds and the Legislature may adopt more expansive limits.
Section 5: Severability
If any provision of this measure or the application thereof to any person or circumstance is held invalid, that invalidity shall not affect other provisions or applications of the measure that can be given effect without the invalid provision or application, and to this end the provisions of this measure are severable.
so I have become a twit…
June 10th, 2009yea I finally went and updated my twitter account. I opened my twitter account about a year ago and well frankly never updated it at all.. yea I know you can add twitter to this and that and that and this and put shit in blogs and all that.. well frankly I’ve not really done anything with it.. but I’ve updated it… so if you want to follow me, not sure why you would but here is the link..
http://twitter.com/evilgenesf
so maybe i’ll even install a twit app on my itouch.. who knows.. maybe I will maybe I wont. stay tune.
So plenty is going on in my life now. I just finished a great 10 day vacation in Chicago to see reX. Man I miss him. It was super great to hang out with him Ty, the kitties and Craig. Here are two images from my trip.. you can see the rest on myspace, facebook and mysite (if I ever finish uploading them).

reX and eVil
I had a great time. No only did I get to hang out with reX and make a few new friends. I got to finally meet the guys from Qnation.FM. Meeting Viz & Cole and Imajin was a blast.

Qnation.FM hookers
They are a great bunch of guys. Yea I did get to see Brent Corrigan and Grant again was nice to get a little chat time in with them, even tho it was at events and stuff around the Grabbys I did get some time in. I did finally get to meet Albert as well. He’s a great guy and you can see him on Dwaynes Blog doing super great interviews..
Now I’m done talking about the fun the last month.. lets get into the no so fun.. Well I’ve been planning on moving out of Berkeley with my roommate the last few months and something has delayed us.. well now its a whole new thing this time around. I wont go into details here but we are either going to move out in a week or stay for the next 6 months and then move to SF. Whichever way it goes one thing is clear Mikey and I will no longer be roommates.
The last year in Berkeley has damaged our friendship and well he said if we go our seperate ways we might beable to salavage our friendship. Frankly I’d like that but I honestly do not think he wants too, but only time will tell.
So my next post might be that we are staying or leaving.. keep your fingers crossed.. well I need to get some “work” done.. everyone go to RECESSION tonight at Deco… if you are on facebook go here.. http://www.facebook.com/event.php?eid=99121944352

Recession @ Deco at 9pm
so if you are in SF come out tonight.. it should be fun.. oh yea on last blurb
check out Adam’s Youtube post..its fun
Changed my middle name to Equality on Facebook Bad mouthing Iowa
U.S. Supreme Court rejects Prop. 215 challenge
May 18th, 2009just saw this on SF gate, and HAD to share.. thanks AP and SF gate.. Bob Egelko, Chronicle Staff Writer
California’s medical marijuana law survived its most serious legal challenge today as the U.S. Supreme Court denied appeals by two counties that argued they were being forced to condone violations of federal drug laws.
The justices, without comment, denied a hearing to officials from San Diego and San Bernardino counties who challenged Proposition 215, an initiative approved by state voters in 1996 that became a model for laws in 12 other states. It allows patients to use marijuana for medical conditions with their doctor’s recommendation.
The counties specifically objected to legislation requiring them to issue identification cards that protect holders from arrest by state or local police for possessing small amounts of marijuana for medical use.
The U.S. Supreme Court has ruled that the federal government can enforce its laws against marijuana to prosecute users and suppliers of the drug in California and the other 12 states. The Obama administration has said it will target only traffickers who violate state as well as federal laws, although it has not stopped U.S. attorneys from raiding dispensaries that operate with local government approval.
Prop. 215 remains in effect despite federal enforcement efforts that began as soon as it passed. In the counties’ case, the Supreme Court left intact a state ruling last year that said California remains free to decide whether to punish drug users under its own laws.
“The purpose of the (federal law) is to combat recreational drug use, not to regulate a state’s medical practices,” the Fourth District Court of Appeal in San Diego said in the July 31 decision.
In seeking Supreme Court review, San Diego and San Bernardino counties argued that the federal drug law overrides Prop. 215 and that they should not be required to issue identification cards allowing conduct that violates federal law.
Medical marijuana advocates were relieved by today’s order.
“This was the most threatening case to state medical marijuana laws, the only one that tried to invalidate state laws,” said attorney Graham Boyd of the American Civil Liberties Union, which defended the California law in the appeals court.
“No longer will local officials be able to hide behind federal law and resist upholding California’s medical marijuana law,” said Joe Elford, lawyer for Americans for Safe Access, which also took part in the case. He said the decision would strengthen his organization’s case against the two counties and eight others that have refused to issue the identification cards.
The cases are San Diego County vs. San Diego NORML, 08-887, and San Bernardino County vs. California, 08-897.
Interim Guidance on Antiviral Recommendations for Patients with Confirmed or Suspected Swine Influenza A (H1N1) Virus Infection and Close Contacts
May 4th, 2009

(H1N1) Virus Infection
Objective: To provide interim guidance on the use of antiviral agents for treatment and chemoprophylaxis of swine influenza A (H1N1) virus infection. This includes patients with confirmed, probable or suspected swine influenza A (H1N1) virus infection and their close contacts.
Case Definitions for Infection with Swine-origin Influenza A (H1N1) Virus (S-OIV)
A confirmed case of S-OIV infection is defined as a person with an acute febrile respiratory illness with laboratory confirmed S-OIV infection at CDC by one or more of the following tests:
- real-time RT-PCR
- viral culture
A probable case of S-OIV infection is defined as a person with an acute febrile respiratory illness who is positive for influenza A, but negative for H1 and H3 by influenza RT-PCR
A suspected case of S-OIV infection is defined as a person with acute febrile respiratory illness with onset
- within 7 days of close contact with a person who is a confirmed case of S-OIV infection, or
- within 7 days of travel to community either within the United States or internationally where there are one or more confirmed cases of S-OIV infection, or
- resides in a community where there are one or more confirmed cases of S-OIV infection.
Infectious period for a confirmed case of swine influenza A (H1N1) virus infection is defined as 1 day prior to the case’s illness onset to 7 days after onset.
Close contact is defined as: within about 6 feet of an ill person who is a confirmed or suspected case of swine-origin influenza A (H1N1) virus infection during the case’s infectious period.
Acute respiratory illness is defined as recent onset of at least two of the following: rhinorrhea or nasal congestion, sore throat, cough (with or without fever or feverishness)
High-risk groups: A person who is at high-risk for complications of swine influenza A (H1N1) virus infection is defined as the same for seasonal influenza (see MMWR: Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008).
Special Considerations for Children
Aspirin or aspirin-containing products (e.g. bismuth subsalicylate – Pepto Bismol) should not be administered to any confirmed or suspected ill case of swine influenza A (H1N1) virus infection aged 18 years old and younger due to the risk of Reye syndrome. For relief of fever, other anti-pyretic medications are recommended such as acetaminophen or non steroidal anti-inflammatory drugs.
Antiviral Resistance
This swine influenza A (H1N1) virus is sensitive (susceptible) to the neuraminidase inhibitor antiviral medications zanamivir and oseltamivir. It is resistant to the adamantane antiviral medications, amantadine and rimantadine.
Antiviral Treatment
Confirmed, Probable and Suspected Cases of Swine-origin Influenza A (H1N1) Virus Infection
Recommendations for use of antivirals may change as data on antiviral effectiveness, clinical spectrum of illness, adverse events from antiviral use, and antiviral susceptibility data become available.
Antiviral treatment should be considered for confirmed, probable or suspected cases of swine-origin influenza A (H1N1) virus infection. Treatment of hospitalized patients and patients at higher risk for influenza complications should be prioritized.
Only RT-PCR or viral culture can confirm infection with swine-origin influenza A (H1N1) virus. The test performance of rapid antigen tests and immunofluorescence tests for detection of swine-origin influenza A (H1N1) virus is unknown. Persons who might have swine-origin influenza A (H1N1) virus and who test positive for influenza A using one of these tests should have confirmatory RT-PCR or viral culture testing to confirm the presence of swine-origin influenza A (H1N1) virus. A negative rapid antigen or immunofluorescence test cannot be used to rule out swine-origin influenza A (H1N1) virus infection.
Antiviral treatment with zanamivir or oseltamivir should be initiated as soon as possible after the onset of symptoms. Evidence for benefits from treatment in studies of seasonal influenza is strongest when treatment is started within 48 hours of illness onset. However, some studies of treatment of seasonal influenza have indicated benefit, including reductions in mortality or duration of hospitalization even for patients whose treatment was started more than 48 hours after illness onset. Recommended duration of treatment is five days. Recommendations for use of antivirals may change as data on antiviral susceptibilities and effectiveness become available. Antiviral doses recommended for treatment of swine-origin influenza A (H1N1) virus infection in adults or children 1 year of age or older are the same as those recommended for seasonal influenza (Table 1). Oseltamivir use for children < 1 year old was recently approved by the U.S. Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA), and dosing for these children is age-based (Table 2).
Note: Areas that continue to have seasonal influenza activity, especially those with circulation of oseltamivir-resistant human A (H1N1) viruses, might prefer to use either zanamivir or a combination of oseltamivir and rimantadine or amantadine to provide adequate empiric treatment or chemoprophylaxis for patients who might have human influenza A (H1N1) infection.
Antiviral Chemoprophylaxis
For antiviral chemoprophylaxis of swine-origin influenza A (H1N1) virus infection, either oseltamivir or zanamivir are recommended (Table 1). Duration of antiviral chemoprophylaxis post-exposure is 10 days after the last known exposure to an ill confirmed case of swine-origin influenza A (H1N1) virus infection. Post exposure prophylaxis should be considered for contact during the infectious period (e.g., one day before until 7 days after the case’s onset of illness). If the contact occurred more than 7 days earlier, then prophylaxis is not necessary. For pre-exposure protection, chemoprophylaxis should be given during the potential exposure period and continued for 10 days after the last known exposure to an ill confirmed case of swine-origin influenza A (H1N1) virus infection. Oseltamivir can also be used for chemoprophylaxis under the EUA (Table 3).
Antiviral chemoprophylaxis with either oseltamivir or zanamivir is recommended for the following individuals:
- Household close contacts who are at high-risk for complications of influenza (e.g., persons with certain chronic medical conditions, persons 65 or older, children younger than 5 years old, and pregnant women) of a confirmed or probable case.
- Health care workers or public health workers who were not using appropriate personal protective equipment during close contact with an ill confirmed, probable, or suspect case of swine-origin influenza A (H1N1) virus infection during the case’s infectious period. See guidelines on personal protective equipment.
Antiviral chemoprophylaxis with either oseltamivir or zanamivir can be considered for the following:
- Household close contacts who are at high-risk for complications of influenza (e.g., persons with certain chronic medical conditions, persons 65 years or older, children younger than 5 years old, and pregnant women) of a suspected case.
- Children attending school or daycare who are at high-risk for complications of influenza (children with certain chronic medical conditions) and who had close contact (face-to-face) with a confirmed, probable, or suspected case.
- Health care workers who are at high-risk for complications of influenza (e.g., persons with certain chronic medical conditions, persons 65 or older, and pregnant women) who are working in an area of the healthcare facility that contains patients with confirmed swine-origin influenza A (H1N1) cases, or who is caring for patients with any acute febrile respiratory illness.
- Travelers to Mexico who are at high-risk for complications of influenza (e.g., persons with certain chronic medical conditions, persons 65 or older, children younger than 5 years old, and pregnant women). (Note: A travel warning is currently in effect indicating that nonessential travel to Mexico should be avoided.
- First responders who are at high-risk for complications of influenza (e.g., persons with certain chronic medical conditions, persons 65 or older, children younger than 5 years old, and pregnant women) and who are working in areas with confirmed cases of swine-origin influenza A (H1N1) virus infection.
| Agent, group | Treatment | Chemoprophylaxis | |
|---|---|---|---|
| Oseltamivir | |||
| Adults | 75‐mg capsule twice per day for 5 days | 75‐mg capsule once per day | |
| Children (age, 12 months or older), weight: | 15 kg or less | 60 mg per day divided into 2 doses | 30 mg once per day |
| 15–23 kg | 90 mg per day divided into 2 doses | 45 mg once per day | |
| 24–40 kg | 120 mg per day divided into 2 doses | 60 mg once per day | |
| >40 kg | 150 mg per day divided into 2 doses | 75 mg once per day | |
| Zanamivir | |||
| Adults | Two 5‐mg inhalations (10 mg total) twice per day | Two 5‐mg inhalations (10 mg total) once per day | |
| Children | Two 5‐mg inhalations (10 mg total) twice per day (age, 7 years or older) | Two 5‐mg inhalations (10 mg total) once per day (age, 5 years or older) | |
Children Under 1 Year of Age
Children under one year of age are at high risk for complications from seasonal human influenza virus infections. The characteristics of human infections with swine-origin H1N1 viruses are still being studied, and it is not known whether infants are at higher risk for complications associated with swine-origin H1N1 infection compared to older children and adults. Limited safety data on the use of oseltamivir (or zanamivir) are available from children less than one year of age, and oseltamivir is not licensed for use in children less than 1 year of age. Available data come from use of oseltamivir for treatment of seasonal influenza. These data suggest that severe adverse events are rare, and the Infectious Diseases Society of America recently noted, with regard to use of oseltamivir in children younger than 1 year old with seasonal influenza, that “…limited retrospective data on the safety and efficacy of oseltamivir in this young age group have not demonstrated age-specific drug-attributable toxicities to date.” (See IDSA guidelines for seasonal influenza
.)
Because infants typically have high rates of morbidity and mortality from influenza, infants with swine-origin influenza A (H1N1) infections may benefit from treatment using oseltamivir.
Healthcare providers should be aware of the lack of data on safety and dosing when considering oseltamivir use in a seriously ill young infant with confirmed swine-origin H1N1 influenza or who has been exposed to a confirmed swine H1N1 case, and carefully monitor infants for adverse events when oseltamivir is used. See additional information on oseltamivir for this age group.
Pregnant Women
Oseltamivir and zanamivir are “Pregnancy Category C” medications, indicating that no clinical studies have been conducted to assess the safety of these medications for pregnant women. Because of the unknown effects of influenza antiviral drugs on pregnant women and their fetuses, oseltamivir or zanamivir should be used during pregnancy only if the potential benefit justifies the potential risk to the embryo or fetus; the manufacturers’ package inserts should be consulted. However, no adverse effects have been reported among women who received oseltamivir or zanamivir during pregnancy or among infants born to women who have received oseltamivir or zanamivir. Pregnancy should not be considered a contraindication to oseltamivir or zanamivir use. Because of its systemic activity, oseltamivir is preferred for treatment of pregnant women. The drug of choice for prophylaxis is less clear. Zanamivir may be preferable because of its limited systemic absorption; however, respiratory complications that may be associated with zanamivir because of its inhaled route of administration need to be considered, especially in women at risk for respiratory problems.
Adverse Events and Contraindications
For further information about influenza antiviral medications, including contraindications and adverse effects, please see the following:
- Antiviral Agents for Seasonal Influenza: Side Effects and Adverse Reactions
- MMWR: Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008
MMWR August 8, 2008 / 57(RR07);1-60
Adverse events from influenza antiviral medications should be reported through the U.S. FDA Medwatch website
.
- Links to non-federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the federal government, and none should be inferred. CDC is not responsible for the content of the individual organization Web pages found at these links.
Influenza A(H1N1) – update 14
May 4th, 2009
Swine Flu
4 May 2009 — As of 18:00 GMT, 4 May 2009, 21 countries have officially reported 1085 cases of influenza A (H1N1) infection.
Mexico has reported 590 laboratory confirmed human cases of infection, including 25 deaths. The United States has reported 286 laboratory confirmed human cases, including one death.
The following countries have reported laboratory confirmed cases with no deaths – Austria (1), Canada (101), China, Hong Kong Special Administrative Region (1), Costa Rica (1), Colombia (1), Denmark (1), El Salvador (2), France (4), Germany (8), Ireland (1), Israel (4), Italy (2), Netherlands (1), New Zealand (6), Portugal (1), Republic of Korea (1), Spain (54), Switzerland (1) and the United Kingdom (18).
It is considered prudent for people who are ill to delay international travel and for people developing symptoms following international travel to seek medical attention, in line with guidance from national authorities. Individuals are advised to wash hands thoroughly with soap and water on a regular basis and should seek medical attention if they develop any symptoms of influenza-like illness.
WHO advises no restriction of regular travel or closure of borders.
There is no risk of infection from this virus from consumption of well-cooked pork and pork products.
Further information on the situation will be available on the WHO website on a regular basis.
Influenza A(H1N1) – update 13
4 May 2009 — As of 06:00 GMT, 4 May 2009, 20 countries have officially reported 985 cases of influenza A (H1N1) infection.
|
Map of the spread of Infuenza A(H1N1): number of laboratory confirmed cases and deaths |
Mexico has reported 590 laboratory confirmed human cases of infection, including 25 deaths. The higher number of cases from Mexico reflects ongoing testing of previously collected specimens. The United States has reported 226 laboratory confirmed human cases, including one death.
The following countries have reported laboratory confirmed cases with no deaths – Austria (1), Canada (85), China, Hong Kong Special Administrative Region (1), Costa Rica (1), Colombia (1), Denmark (1), El Salvador (2), France (2), Germany (8), Ireland (1), Israel (3), Italy (1), Netherlands (1), New Zealand (4), Republic of Korea (1), Spain (40), Switzerland (1) and the United Kingdom (15).
There is no risk of infection from this virus from consumption of well-cooked pork and pork products.
It is considered prudent for people who are ill to delay international travel and for people developing symptoms following international travel to seek medical attention, in line with guidance from national authorities. Individuals are advised to wash hands thoroughly with soap and water on a regular basis and should seek medical attention if they develop any symptoms of influenza-like illness.
WHO advises no restriction of regular travel or closure of borders.
Further information on the situation will be available on the WHO website on a regular basis.

Map of the spread of Infuenza A(H1N1): number of laboratory confirmed cases and deaths
